Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

nformation, go to http://www.gen-probe.com.

Trademarks

APTIMA, APTIMA COMBO 2, PACE, PROGENSA and TIGRIS are trademarks of Gen-Probe Incorporated. ULTRIO and PROCLEIX are trademarks of Chiron, a business unit of Novartis Vaccines and Diagnostics. All other trademarks are the property of their owners.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those under the heading "Updated 2008 Financial Guidance," are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning Gen-Probe's financial condition, possible or expected results of operations, regulatory approvals, future milestone payments, growth opportunities, and plans and objectives of management are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2008 growth, revenue, earnings or other financial targets, (ii) the risk that we may not earn or receive milestone payments from our collaborators, including Novartis, (iii) the possibility that the market for the sale of our new products, such as our TIGRIS system, APTIMA Combo 2 assay, PROCLEIX ULTRIO assay and PROGENSA PCA3 assay, may not develop as expected, (iv) the enhancement of existing products and the development of new products, including products, if any, to be developed unde
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... Sept. 2, 2015 Australian prostate cancer technology ... Australian science prize recognising ,outstanding, science that uses its ... globally launch a novel prostate cancer diagnostic test known ... level consortium taking out the peer-reviewed Australian Museum Eureka ... This prize is awarded for ground ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... of researchers has proposed a way to turn the material ... of electrons with a laser "on-off switch". Graphene is ... carbon atoms only one-atom thick, but 200 times stronger than ... than any other known material. It is almost completely transparent, ...
... June 17, 2011 Kendle International Inc. (Nasdaq: ... increased the consideration amount offered for its cash tender ... its $142.5 million aggregate principal amount of outstanding 3.375% ... No. US48880LAA52) (the "Notes").  The consideration for each $1,000.00 ...
... have been proposed for cell-based diagnostics and regenerative medicine ... develop into a desired cell type -- such as ... the clinical potential of these technologies. New research ... of the International Society for Stem Cell Research (ISSCR) ...
Cached Biology Technology:Graphene may gain an 'on-off switch,' adding semiconductor to long list of material's achievements 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/26/2015)... August 26, 2015 The report "Multi-Factor ... Five Factor), Application (Travel & Immigration, Government, Banking, Defense, ... Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market ... growing at a CAGR of 17.7% between 2015 and ... F igures spread through 169 P ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... presented at IAS build a compelling case for FUZEON ... the newest drugs to give patients facing resistance their ... treatment goal for all people living with HIV. , ... for all triple-class experienced patients. FUZEON combined with the ...
... A computer scientist at Washington University in St. Louis ... genome of a worm and has found 150 genes ... using the software, he and his colleagues have developed ... genes. , Michael Brent, Ph.D., Washington University professor of ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Newest HIV drugs should be used with FUZEON(R) 2Newest HIV drugs should be used with FUZEON(R) 3Program finds lost genes in nematode genome 2Program finds lost genes in nematode genome 3Candida albicans Genome Fully Annotated 2Candida albicans Genome Fully Annotated 3
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
... Streptavidin Sepharose High Performance, 5 ml. ... used in HiTrap Streptavidin columns for ... for packing into Tricorn 5/50 GL, ... larger scale purifications are required.Extremely useful ...
... Clone/PAD: ZMD.366. Immunogen: ... internal region of human SENP1. ... human ~73 kDa SENP1. ... or DYKDDDDK)-HA-tagged-SENP1 transfected Hep2 cell ...
...
Biology Products: